Accretion Pharmaceuticals Limited (NSE:ACCPL)

India · Delayed Price · Currency is INR

203.30

-1.70 (-0.83%)

At close: Sep 25, 2026

Market Cap	2.26B +234.1%
Revenue (ttm)	896.27M +56.2%
Net Income	96.68M +42.3%
EPS	9.03 +6.5%
Shares Out	11.12M
PE Ratio	22.51
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	18,000
Open	200.00
Previous Close	205.00
Day's Range	198.00 - 205.00
52-Week Range	53.80 - 219.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 13, 2026

About Accretion Pharmaceuticals

Accretion Pharmaceuticals Limited engages in the manufacturing and marketing of pharmaceutical products in India. The company offers antibiotic, antibacterial, antifungal, anti-inflammatory, anti-spasmodic, antihistamine, antiallergy, anticough, anticold, antiulcer, gastrointestinal, antacid, anti-diabetic, cardiac, anti-hypertensive, psychotropic, memory enhancer, vitamins, supplements, and other products. It also provides external preparation, oral powder, effervescent formulation, and nutraceutical products, as well as formulations for brain... [Read more]

Industry Pharmaceutical Preparations

Founded 2012

Employees 132

Stock Exchange National Stock Exchange of India

Ticker Symbol ACCPL

Full Company Profile

Financial Performance

In fiscal year 2026, Accretion Pharmaceuticals's revenue was 896.27 million, an increase of 56.21% compared to the previous year's 573.76 million. Earnings were 96.68 million, an increase of 42.31%.

Financial Statements